<DOC>
<DOCNO>EP-0646116</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PROCESS AND INTERMEDIATES FOR BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31495	C07D47104	A61K31505	A61K31435	A61K31495	A61K31505	A61K31435	C07D47100	A61P2500	A61P2520	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	A61K	A61K	A61K	A61K	A61K	C07D	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D471	A61K31	A61K31	A61K31	A61K31	A61K31	C07D471	A61P25	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Optically pure intermediates of formula (1) wherein the substituent B is either cis or trans to the C9a-C1 bond and is selected from the group consisting of -CH2OH, -CHO, -CH2OSO2R, -CH2CN, -CH(OH)CH2NO2, -CH=CH-NO2, (2) and (3), C is selected from the group consisting of -H, (4), (5), and a nitrogen protecting group which is removable by hydrogenation or acid treatment; and wherein R is (C1-C8) alkyl, phenyl or alkyl substituted phenyl; X is N or CH; Y is O or S and Z is H or Cl; for the synthesis of octahydro-1H-pyrido(1,2-a)pyrazinyl ethyl carboxamide anxiolytic agents.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The present invention is directed to an improved process for intermediates
useful for the synthesis of the anxiolytic agents represented by structures I and II below
as well as intermediate compounds. Commonly owned
European patent application 380,217, filed January 12, 1990 and United States patent
applications Serial No.'s 661,791, filed February 27, 1991 (PCT/US91/08378, filed
November 18, 1991); 661,726, filed February 27, 1991; and 661,730, filed February 27,
1991 (PCT/US91/08400, filed November 19, 1991) described the synthesis of
Compound I and related intermediates in Scheme A shown below. 
Commonly owned U.S. Patent Application Serial No. 765,332, filed September
25, 1991 claims an alpha-hydroxy derivative of Compound I with the structure shown
below as Compound II.
U.S. 4,956,368 teaches that compounds hydroxylated at C-6 of the
azaspirodecanedione portion of a molecule may rearrange to produce an
oxaspirononanone of the type;
The text of commonly owned United States Patent Application Serial Nos.
661,791; 661,726; 661,730; and 765,332 is herein incorporated by reference.The present invention is directed toward an improved process for the synthesis
of anxiolytic agents of Compounds I and II above and intermediate compounds used
in this synthesis. The new synthesis provides Compound I in an overall yield of approximately 8%
based on pyridine diester, representing an approximate 5 fold improvement over
previous syntheses.In one aspect this invention is directed toward substantially optically pure
intermediate compounds of the formula:

wherein the substituent B is either cis or trans to the C9a-C1 bond and is selected from
the group consisting of
-CH2OH, -CHO, -CH2OSO2R, -CH2CN, -CH(OH)CH2NO2 and -CH=CH-NO2; 
C is selected from the group consisting of -H,

and a nitrogen protecting group which is removable by hydrogenation or acid
treatment; and wherein R is (C1-C6) alkyl, phenyl or alkyl substituted phenyl; X is N or
CH; Y is O or S; and Z is H or Cl; and with the proviso that when B is cis to the C9a-C1
bond, B must be -CH2OH or -CHO, and C must be a group other than -H; and acid
salts thereof.The preferred value of C is

wherein Y is O and Z is H. The preferred value of R is methyl; and the preferred amine
protecting group is tert-butoxycarbonyl.In another aspect, this invention is directed toward a process for preparing a
substantially optically pure compound of the formula
 
having (7R,9aS-Trans) configuration wherein C is selected from the group consisting
of

and a nitrogen protecting
</DESCRIPTION>
<CLAIMS>
A process for preparing a substantially optically pure compound of the formula


having (7R,9aS-Trans) configuration wherein C is selected from the group consisting
of


 
and a nitrogen protecting group which is removable by hydrogenation or acid

treatment; wherein X is N or CH; Y is O or S and Z is H or Cl; comprising:

(a) reacting an activated form of C with a racemic compound of the formula


   in a reaction inert solvent with an acid acceptor to form a racemic
product which has formula


(b) reacting the racemic product of step (a) with a slight molar excess of D-(-)-tartaric
acid in a reaction inert solvent forming two diasteromeric salts;
(c) separating the diasteromeric salts of step (b) and treating the salt having
(7S,9as-Cis) configuration with base to obtain a compound which has

the formula


   having (7S,9aS-Cis) configuration;
(d) oxidizing the product of step (c) to form a product of the formula 


   having (7S,9aS-Cis) configuration.
(e) Isomerizing the product of step (d) to produce a compound of the
formula



   having (7R,9aS-Trans) configuration.
A process for preparing a substantially optically pure compound of the formula


having (7S,9aS-Trans) configuration where in C is selected from the group
consisting of H,


 
and a nitrogen protecting group which is removable by treatment with a strong acid;

wherein X is N or CH; Y is O or S; and Z is H or Cl comprising:

(a) isomerizing a compound of the formula


   having (7S,9aS-Cis) configuration wherein C is selected from the group
consisting of



   and a nitrogen protecting group removable by treatment with strong
acid; wherein X is N or CH; Y is O or S and Z is H or Cl; thereby

converting said compound to the (7R,9aS-Trans) configuration; and
without isolation adding excess nitromethane and stirring until the

reaction is complete to cbtain a compound having the formula

 
   having (7R,9aS-Trans) configuration;
(b) reacting the product of step (a) with an acid anhydride and a weak
organic base in a reaction inert solvent to produce a compound having

the formula


   with a (7S,9aS-Trans) configuration;
(c) reducing the compound of step (b) to produce a compound having the
formula



   with a (7S,9aS-Trans) configuration; wherein C is selected from the
group consisting of



   and a nitrogen protecting group which is removable by treatment with
a strong acid, wherein X is NH or CH; Y is O or S; and Z is H or Cl; 
(d) reacting the product of step (c) wherein C is an amine protecting group
which is removable with strong acid, with strong acid in a reaction inert

solvent and neutralized with base producing a product having the
formula



   with a (7S,9aS-Trans) configuration.
A process for preparing a substantially optically pure compound of the formula


having (7S,9aS-Trans) configuration where in C is selected from the group consisting
of H,



and a nitrogen protecting group which is removable by treatment with a strong acid;
wherein X is N or CH; Y is O or S; and Z is H or Cl; comprising:


(a) reacting a compound of the formula 


   having (7R, 9aS-Trans) configuration wherein C is selected from the
group consisting of



   and a nitrogen protecting group removable by treatment with strong
acid; wherein X is N or CH; Y is O or S and Z is H or Cl; with a reducing

agent to produce a compound of the formula


   having (7R,9aS-Trans) configuration;
(b) reacting the product of step (a) with a (C
1
-C
6
)alkyl, phenyl or alkyl
substituted phenyl sulfonyl chloride in a reaction inert solvent and in the

presence of a base to form a compound of the formula 


having (7R,9aS-Trans) configuration; wherein R is (C
1
-C
6
)alkyl, phenyl or
alkyl substituted phenyl
(c) reacting the product of step (b) with an alkali metal cyanide in a reaction
inert solvent to form a compound of the formula



   having (7S,9aS-Trans) configuration;
(d) reducing the product of step (c) to form a compound of the formula


   with a (7S,9aS-Trans) configuration; wherein C is selected from the
group consisting of 



and a nitrogen protecting group which is removable by treatment with
a strong acid, wherein X is NH or CH; Y is O or S; and Z is H or Cl;
(e) reacting the product of step (d) wherein C is an amine protecting group
which is removable with strong acid, with strong acid in a reaction inert

solvent and neutralizing with base to produce a compound having the
formula



   with a (7S,9aS-Trans) configuration.
A substantially optically pure compound of the formula


wherein the substituent B is either cis or trans to the C
9a
-C
1
 bond and is selected from
the group consisting of -CH
2
OH, -CHO, -CH
2
OSO
2
R, -CH
2
CN, -CH(OH)CH
2
NO
2
 and
-CH=CH-NO
2
; 
C is selected from the group consisting of -H,



and a nitrogen protecting group which is removable by hydrogenation or acid
treatment; and wherein R is (C
1
-C
6
)alkyl, phenyl or alkyl substituted phenyl; X is N or
CH; Y is O or S; and Z is H or Cl; and with the proviso that if B is cis to the C
9a
-C
1

bond, B must be -CHO and C must be a group other than -H; and acid salts thereof.
A compound of claim 4 wherein C is 1,2-benzisoxazol-3-yl or tert-butoxycarbonyl.
The compound of claim 4 which is (7S,9aS)-Cis-7-formyl-2-(1,2-benzisoxazol-3-yl)-23,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7R,9aS)-Trans-7-formyl-2-(1,2-benzisoxazol-3-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7R,9aS)-Trans-7-hydroxymethyl-2-(1,2-benzisoxazol-3-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7R,9aS)-Trans-7-(methanesulfonyloxymethyl)-2-(1,2-benzisoxazol-3-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7S,9aS)-Trans-7-(cyanomethyl)-2-(1,2-benzisoxazol-3-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7R,9aS)-Trans-7-(1-hydroxy-2-nitroethyl)-2-(1,2-benzisoxazol-3-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7S,9aS)-Trans-7-(2-nitroethylenyl)-2-(1,2-benzisoxazol-3-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine. 
The compound of claim 4 which is (7S,9aS)-Cis-7-formyl-2-(tert.-butoxycarbonyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7R,9aS)-Trans-7-formyl-2-(tert.butoxycarbonyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7R,9aS)-trans-7-(hydroxymethyl)-2-(tert.-butoxycarbonyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7R,9aS)-Trans-7-(1-hydroxy-2-nitroethyl)-2-(tert.-butoxycarbonyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.
The compound of claim 4 which is (7S,-9aS)-Trans-7-(2-nitroethylenyl)-2-(tert.-butoxycarbonyl)-2,3,4,6,7,8,9,
9a-octahydro-1H-pyrido[1,2-a]
pyrazine.
</CLAIMS>
</TEXT>
</DOC>
